1 death (n = 55; 6.3%) occurred at 8.4 years (
median time).
2 n time, 134.5 minutes to quarter 3 year 2016
median time,
128 minutes, P=0.002).
3 door to first pass time (quarter 4 year 2014
median time,
134.5 minutes to quarter 3 year 2016 median
4 ent cases of breast cancer during follow-up (
median time:
5.2 years).
5 n after initiation of antimicrobial therapy (
median time,
70 minutes [interquartile range, 50 to 110
6 HLA donor-specific antibodies (dnDSAs) at a
median time after transplantation of 19.0 months.
7 The
median time between anti-TNFalpha treatment and recurren
8 Median time between blood collection and ALS death was 8
9 The
median time between consent and transplantation of a kid
10 Median time between CT acquisition and report was 25 min
11 The
median time between CT and MRI was 35 minutes (interquar
12 Median time between disclosure to the proband and counse
13 Median time between first and reinfection swab was 64.5
14 Median time between initial alert and readmission was 6.
15 The
median time between invitations (2.37 years) was used as
16 Median time between isolate referral and initial genomic
17 Median time between metal measurement and brain imaging
18 The
median time between prior therapy and trial enrollment w
19 CI or TT using baseline and follow-up scans (
median time between scans, 4.2 mo).
20 sion assays at baseline and follow-up with a
median time between studies of 1.5 months.
21 Median time between successful contacts was 3.0 (IQR, 3.
22 The
median time between TAVI and stroke was 1 day (interquar
23 The
median time between vitreoretinal surgery and orbital em
24 Median time elapsed since surgery was 7 years and mean a
25 The
median time for patients to achieve a BCVA of 20/40 or b
26 BCVA of 20/40 or better was 59 days and the
median time for patients to gain 15 or more ETDRS letter
27 The
median time for PED development after hematopoietic stem
28 The
median time for RTx workup was 5.4 (2.4-9.4) in group A
29 Median time from ablation to death was 11.6 (interquarti
30 The
median time from admission to test result of the rapid t
31 Median age was 57 years (range 27-76), and
median time from alloHCT to enrollment was 21 months (ra
32 The
median time from antifungal treatment to steroid initiat
33 Median time from autoHCT to vaccination was 2.3 months.
34 The
median time from baseline obesity diagnosis until death
35 had significant initial measurement burden (
median time from case completion to submission: 15 mo [i
36 lular therapy (Allo, 35; Auto, 37; CAR T, 5;
median time from cellular therapy, 782 days; IQR, 354-16
37 The
median time from CHiP referral of HIV-positive individua
38 t diagnosis 5 years [IQR 3.1-9.1 years], and
median time from diagnosis of 30.0 years [22.7-36.3]) ha
39 death for each type of synucleinopathy, the
median time from diagnosis to death, and the causes of d
40 Median time from diagnosis to enrollment was 23 months (
41 nosis was 7 years (range, 0-20.9 years), and
median time from diagnosis was 29 years (range, 15-47 ye
42 median age, 29 years [range, 6 to 60 years];
median time from diagnosis, 21 years [range, 5 to 44 yea
43 The cohort included 163 patients with
median time from discharge to last recorded follow-up of
44 Median time from ECG to echocardiogram was 1 day (Q1: 1,
45 Median time from emergency room arrival to norepinephrin
46 Median time from enrolment to ART initiation was 0 days
47 The
median time from estimated seroconversion to ART initiat
48 The
median time from estimated seroconversion to ART initiat
49 ver the study period was over $128 M and the
median time from event to case close was over 3 years.
50 The
median time from exercise to onset of severe symptoms re
51 to 6 years (median three samples per person,
median time from first to last sample, 4.3 years).
52 The
median time from HIV infection to Kaposi sarcoma was 20
53 patients with incident thrombocytopenia, the
median time from ICU admission to thrombocytopenia was 2
54 Among survivors, the
median time from incident thrombocytopenia to platelet r
55 The
median time from infusion to data cutoff was 14 months (
56 The
median time from intensive care admission to the CT scan
57 The
median time from last active IBD episode to immunotherap
58 The
median time from liberation of vasopressors to recovery
59 median age of patients was 65 years, and the
median time from lung transplant was 5.6 years.
60 Median time from NP onset to biliary stricture diagnosis
61 (11%) were diagnosed as having hATTR-CM; the
median time from onset of symptoms to clinical diagnosis
62 The
median time from onset of the cardiopulmonary resuscitat
63 Median age was 66.2 years, and
median time from operation to survey was 5.6 years (rang
64 The
median time from palliative care consultation to death w
65 The
median time from PDAC diagnosis to the onset of VTE was
66 Median time from primary LT to ReLT-KT was 151.3 (7.5-28
67 The
median time from procedure to IE hospitalization was 352
68 Median time from randomisation to cessation of convulsiv
69 he patients assigned to undergo surgery, the
median time from randomization to surgery was 3.1 weeks;
70 vs 42 [43.3%] of 97 infants; p<0.0001), the
median time from sample collection to ART initiation amo
71 ceiving conventional testing; p<0.0001), the
median time from sample collection to return of results
72 o had a sediment specimen submitted for PSQ,
median time from specimen collection to MDR-TB treatment
73 The
median time from start of incubation to Cognitor Minus t
74 The
median time from starting immunotherapy to ocular sympto
75 Median time from stroke onset to randomisation was 3.3 h
76 The
median time from study treatment to wire-crossing during
77 The
median time from surgery to LARS assessment was 1065 day
78 ospital within 24 hours after symptom onset (
median time from symptom onset to blood sampling = 3.3 h
79 agnostic age was 60.9 years (IQR 52.7-68.2),
median time from symptom onset to diagnosis was 1.01 yea
80 line was 7.90 (SD 1.82) Log10 copies/mL, and
median time from symptom onset to randomization was 3 da
81 The
median time from the first vial of idarucizumab to surge
82 The
median time from the last injection to the time when cab
83 of Health Stroke Scale of 11 (IQR 6-16) and
median time from the onset of symptoms of intracerebral
84 The
median time from the onset of symptoms to enrollment in
85 The
median time from the start of exercise to onset of sympt
86 Median time from transplant to COVID-19 testing was 2822
87 The
median time from transplant to transplant glomerulopathy
88 Median time from transplant was 5.58 y (interquartile ra
89 The
median time from transplantation to diagnosis was 10.5 y
90 The
median time from Xpert diagnosis to RR-TB treatment init
91 Median times from initial regulatory submission before a
92 The
median time in the trial was 15.9 months.
93 Median time (
interquartile range) from sepsis diagnosis
94 Median time (
interquartile range) of TL measurement was
95 The
median time interval between the two paired assessments
96 re enrolled and had received tamoxifen for a
median time of 0.37 years (range, 0.23 to 0.6 years) bef
97 ion occurred in 99 patients (62.3%) within a
median time of 103 days (interquartile range: 32 to 392
98 P<0.001), were overall shorter in duration (
median time of 11 minutes [8.5-26.5] versus 15 minutes [
99 al of 270 patients presenting an ACS after a
median time of 12 (interquartile range, 5-17) months pos
100 ts presenting with OMG converted to GMG at a
median time of 13 months (range 2-180 months).
101 Eleven patients (34%) died at a
median time of 14 days from admission.
102 lant recipients (38.8%) developed CLAD, in a
median time of 20.4 months (IQR, 12-30.4 months).
103 red repeat intervention for IOP control with
median time of 3.17 years (IQR, 0.92-6.56) from first su
104 Cryptosporidiosis occurred at a
median time of 3.4 (0-19.8) years posttransplant.
105 rcent of patients were discharged alive at a
median time of 30 days (interquartile range, 19-48 d).
106 ing room time plateaued after 240 cases at a
median time of 391 minutes (interquartile rang 340-477).
107 ibition was observed in 91% of patients at a
median time of 58 seconds before syncope.
108 llance colonoscopies and were followed for a
median time of 7.8 years for development of adenomas or
109 experiencing a death equivalent an estimated
median time of 8.4 years after developing systolic dysfu
110 ; 5152 women) at CT and were followed over a
median time of 8.8 years (interquartile range, 5.1-11.6
111 % of INDs obtaining marketing approval, in a
median time of about six years from IND receipt to appro
112 The
median time of day for extubation with an extubation rea
113 y (number of items per 3 months) and timing (
median time of day) of purchases, and participant survey
114 Median time of death for patients with FMF was 61 months
115 The
median time of hypotension per patient was 8.0 minutes (
116 ischemic stroke patients were scanned with a
median time of onset to first MRI of 3 hours.
117 Median time of ramipril treatment was 6 months (interqua
118 The
median time of relapse after the most recent infusion wa
119 During a
median time of risk of 8.3 years, skiers had a lower inc
120 triple-negative women were screened after a
median time of six years.
121 The
median time of supine positioning during the first 24 ho
122 Median time of Tpo-RA exposure during pregnancy was 4.4
123 tune each device to optimal performance in a
median time of under 70 minutes.
124 interval [CI], 0.99 to 1.51; P = 0.06), with
median times of 52.3 versus 42.2 h.
125 ge 35 years, median CD4 level 239 cells/ul),
median time on ART at LTFU was 480 days (IQR: 110-1295).
126 Participants'
median time on ART prior to ATI was 3 years, and ATI las
127 Median time on extracorporeal membrane oxygenation befor
128 Median time on natalizumab was 3.3 (range 0-11.6) years;
129 With a
median time on study of 8.9 months, 67% of patients (all
130 Median time on study was 36 weeks (range, 1-120 weeks).
131 8% were male, 77% were born in Asia, and the
median time on treatment was 27.5 months.
132 Median time on waitlist was not statistically different
133 Serum samples were collected over a
median time period of 10 years and analyzed for antibodi
134 224 patients (
median time post-stroke 18 months) completed the 6-month
135 Median age was 58 (IQR 46-57),
median time post-transplant was 5 years (IQR 2-10), 61%
136 Groups differed in
median time posttransplant, for example, R3(injury) 99 d
137 Median time receiving maintenance therapy was 9 months a
138 ery was 0.7% and 2.6%, respectively, and the
median time required to collect the RAI was 33 [IQR 23-5
139 The high
median time-
resolution of 58 years allows the identifica
140 rsus 41 years), sex (62% versus 66% female),
median time since ART initiation (4.8 versus 5.0 years),
141 Forty-five patients were treated;
median time since diagnosis was 14.1 months, and 51% of
142 789 patients with early atrial fibrillation (
median time since diagnosis, 36 days) underwent randomiz
143 The
median time since polycythaemia vera diagnosis was 8.2 y
144 ppression (P = 0.02) at the 2wPP visit, with
median time to <50 copies/mL of 32 vs 72 days.
145 tural valve deterioration was 17.3 years and
median time to all-cause first reintervention was 16.9 y
146 The
median time to alleviation of symptoms was 79.0 hours fo
147 Median time to ALT&100 U/L was 7.5 days (IQR 6 -11) in t
148 r after arrival to the emergency department (
median time to antibiotics, 26 min), which was significa
149 n before the start of the new triage: 67.9% (
median time to antibiotics, 37 min) (p < 0.001).
150 ng 32013 adults entering HIV care in the US,
median time to ART prescription declined from 69 to 6 da
151 late awakening (> 48 hr from sedation stop;
median time to awakening 5 days [range, 3-23 d]) was obs
152 At enrollment (
median time to baseline visit, 358 days after symptom on
153 entasvir and showed rapid viral suppression (
median time to clearance 3.5 days, IQR 0.0-8.3), with th
154 Median time to clearance of the bloodstream was comparab
155 After recognition of HCM-LVSD, the
median time to composite outcome was 8.4 years.
156 Median time to continuous renal replacement therapy comm
157 Median time to core temperature less than 34 degrees C w
158 Median time to CT clearance after azithromycin treatment
159 The
median time to culture conversion was 56 days(95%CI:50-5
160 vs 78.5% [control]; P = .463); however, the
median time to culture conversion was significantly shor
161 The
median time to dementia diagnosis for people prescribed
162 The
median time to detection of adrenal metastasis after ini
163 The
median time to deterioration as determined by FACT-P tot
164 Median time to deterioration in cough, chest pain, or dy
165 Median time to deterioration in FHSI-8 total scores (3.7
166 Median time to deterioration in performance status was 3
167 The
median time to develop severe anaemia was 7.1 weeks(IQR
168 er 1000 textured implants (1 in 871), with a
median time to diagnosis of 10.3 years (range, 6.4-15.5
169 ed clinically recognized opioid abuse with a
median time to diagnosis of 3 years.
170 were diagnosed with jejunal polyposis, with
median time to diagnosis of 55 months and follow up time
171 The
median time to discontinuation of supplemental oxygen wa
172 Among those who discontinued OAC, the
median time to discontinuation was 6.2 months.
173 attacks (rho = 0.24; p < 0.001) and shorter
median time to electrocardiogram for patients with chest
174 Median time to endoscopy was 9 (interquartile range 8-12
175 perior outcomes compared to melphalan alone (
median time to event 40.0 vs 25.0 days, respectively, p
176 Kaplan-Meier methods were used to determine
median time to event for: 1) composite event of known de
177 ompensated heart failure, and 5 arrhythmias;
median time to event of 21 days), all occurred with grad
178 Median time to FACT-P total score deterioration was 14.8
179 The
median time to first and best hematologic response was 4
180 Median time to first CVAE from treatment start was 31 da
181 Median time to first flare was 5.4 years (95% confidence
182 Median time to first implant refill was 8.7, 13.0, and 1
183 g steroids, CSC patients demonstrated longer
median time to first post-diagnosis steroid prescription
184 The
median time to first PrEP discontinuation was 159 days (
185 The
median time to first PrEP discontinuation was 159 days.
186 year, ARD-3150 led to a significantly longer
median time to first pulmonary exacerbation compared wit
187 In ORBIT-3, the
median time to first pulmonary exacerbation was 214 days
188 s of data from both ORBIT-3 and ORBIT-4, the
median time to first pulmonary exacerbation was 222 days
189 In ORBIT-4, the
median time to first pulmonary exacerbation was 230 days
190 Median time to first recurrence by PCR was 118 days (IQR
191 Median time to first refill was 8.7 months, 13.0 months,
192 R 0.188 [95% CI 0.076-0.463]; p<0.0001); the
median time to first relapse was also longer in the toci
193 CR)/CR with incomplete blood count recovery (
median time to first response, 1.4 months).
194 Median time to fixation was 15 hours (IQR 7-24 hours) an
195 fter withdrawal of the IMP for active JIA-U (
median time to flare 188 days [range 42-413 days).
196 Median time to functional recovery was 7 and 9 days in t
197 29 of the 34 patients with progression, the
median time to growth detection was only 14 months for C
198 Median time to haemorrhage was 2.3 years (0.1-12.3).
199 ng people with detectable HCV RNA (n = 325),
median time to HCV RNA detection was 32 minutes and 80%
200 Median time to HCV RNA detection was dependent on HCV RN
201 Median time to heal was 70 days (IQR, 60-96 days) in the
202 ng was observed in 320 (81.4%) wounds with a
median time to healing of 86 days (95% CI: 75-130).
203 Median time to hematological response was 1 week.
204 me to hemostasis was 65+/-157 seconds with a
median time to hemostasis of 24 seconds.
205 ART (dapivirine: 39/65; placebo: 61/93); the
median time to HIV-1 RNA <200 copies/ml was approximatel
206 Median time to hospital discharge was shorter in the NAC
207 lan-Meier curves were constructed to examine
median time to HPV clearance overall, and by selected ri
208 The
median time to in-hospital deterioration was 3 days (IQR
209 Median time to IRIS was 11 days (interquartile range 7-4
210 OS from LT was 12.5 years, with a
median time to LT of 7.5 months [interquartile range, 4.
211 Median time to LT was 12.8 months in long wait regions,
212 Median time to lung cancer diagnosis in patients with (n
213 The
median time to neutrophil recovery was 11.5 days (95% CI
214 near-resolution of pain was 5 days, and the
median time to normalization of the CRP level was 7 days
215 The
median time to normalization of the platelet count was s
216 testing; 24 subsequently developed symptoms (
median time to onset, 4 days).
217 AOT) was more frequent (93.6% and 95.4%) and
median time to optimal therapy (TTOT) was faster (1.3d a
218 omes were similar in both groups and include
median time to oral antibiotic stepdown, LOS, all-cause
219 Median time to pain interference progression was not rea
220 Median time to pain progression was not estimable (NE; 9
221 The
median time to parasitemia was significantly shorter in
222 The
median time to parasitemia was significantly shorter in
223 Median time to PED resolution was 4.5 weeks after starti
224 The
median time to PICC removal was 8.20 days (IQR 4.77-12.1
225 The
median time to platelet recovery was 34 days (95% CI, 32
226 Among them, the
median time to positive Aspergillus culture or GM positi
227 There were 51 (38%) new PPMIs (
median time to PPMI, 5 days).
228 The
median time to pre-eclampsia diagnosis was 4.1 days with
229 stinct risk groups: a high-risk group with a
median time to progression (TTP) of 1.8 years, an interm
230 Median time to progression could not be calculated in th
231 Median time to progression or recurrence for patients in
232 Median time to progression was 39 months (IQR 22-69) for
233 Median time to radiological progression was 6 months (95
234 The
median time to re-activation was 504 days.
235 Median time to re-activation was substantially greater w
236 For these patients, the
median time to readmission was 21.5 days (interquartile
237 The
median time to readmission was 3 days (IQR, 1.0-4.5) for
238 to their presurgical level of function, with
median time to recovery of 2 months (interquartile range
239 recurrence-free survival (P < 0.001), with a
median time to recurrence of 41.2 versus 5.5 months in n
240 The median follow-up was 31.3 months, and
median time to recurrence was 13.3 months.
241 The
median time to recurrence was 25 months after stopping e
242 The
median time to reinfection was 500 days (range 16 to 116
243 The
median time to reinfection was 500 days (range 16-1160)
244 Median time to relapse in the placebo group was 87 days.
245 Median time to relapse was 13 months, with the earliest
246 Among primary PCI patients, the
median time to reperfusion was slightly higher in lower
247 Median time to resolution of ME was 6 months, with compl
248 During the run-in period, the
median time to resolution or near-resolution of pain was
249 Median time to resolution was 22 days for all AEs and th
250 y (PSN) showed a significant decrease of the
median time to resolve PSN after NAB-paclitaxel 125 mg/m
251 Median time to response was 3.9 months (IQR 1.9-7.4).
252 people with undetectable HCV RNA (n = 1061),
median time to result was 57 minutes.
253 Median time to return of spontaneous circulation was 21.
254 Median time to second PGTCS could not be estimated for l
255 The
median time to seroconversion ranged from 10.3-11.0 days
256 sters differ also in treatments received and
median time to shock onset.
257 Median time to sputum culture conversion did not differ
258 The reduction in
median time to sputum culture conversion over 6 months w
259 Median time to stabilization was 3 days (IQR 2-5 days),
260 Median time to stricture resolution was 6.0 months after
261 Median time to structural valve deterioration was 17.3 y
262 The
median time to study notification of a death was 9.1 (IQ
263 Median time to surgery was 11 hours (IQR 4-40).
264 The
median time to surgical explant was 212 days, whereas 8.
265 The
median time to switch was 68 weeks (IQR: 35-127), result
266 Median time to symptom progression was 89 days (range: 1
267 Median time to symptomatic skeletal events was NE (95% C
268 The
median time to target temperature was 5.4 hours in the i
269 The
median time to the development of symptomatic systemic s
270 The
median time to the diagnosis of type 1 diabetes was 48.4
271 adjudicated recurrence to be calculated; the
median time to the first adjudicated recurrence in the p
272 nts in the rilonacept group to allow for the
median time to the first adjudicated recurrence to be ca
273 In the full analysis set,
median time to the first relapse was longer in the tocil
274 The
median time to the next exacerbation was 32.5 days (inte
275 Median time to transformation was 17.8 months (95% CI, 1
276 oup and in 386 (49.0%) in the control group (
median time to transfusion, 1.3 hours vs. 24.9 hours aft
277 Median time to transplant from KPD entry for compatible
278 Median time to transplantation for such patients is doub
279 IQR 15.3-not reached [NR]) months, while the
median time to treatment failure time for those receivin
280 a median follow-up of 11 months (IQR 6-18),
median time to treatment failure was 6.7 months (95% CI
281 142 log10 TCID50/mL.h, respectively, and the
median time to virus nondetection was 117, 75.3, and 108
282 y was performed in 28.5% of patients, with a
median time to vitrectomy of 63 days.
283 The
median time to VRE BSI and non-VRE BSI were D11 and D15,
284 Median time to worst pain intensity progression was 19.0
285 patients with reduced PAM immunoreactivity:
median times to death were 11.3 (PAM-negative), 29.4 (PA
286 Median times to neutrophil and platelet engraftment were
287 The minimum and
median times to sudden death were 0.25 and 92 days, resp
288 Median time-
to-death is approximately 1 week.
289 Median time-
to-death was 8 days (interquartile range, 3-
290 discharged from the hospital alive, but the
median time-
to-discharge is 1 month.
291 GVHD was observed in 8.8% (39/445);
median time-
to-GVHD development (range) was 1.5 months (
292 Median time-
to-remission of scleritis=3.1 years (95% con
293 significant between-group difference in the
median time until the first exacerbation, which was 202
294 g per deciliter (range, 1.1 to 5.8), and the
median time until the first increase of more than 1.0 g
295 The
median time was 13 months to reach a 40% improvement in
296 was 3.3 days (95% CI, 3.2-3.5 days) and the
median time was 3 days (range, 2-7 days).
297 rative fracture was 96 +/- 125 days, and the
median time was 61 (IQR 48-144) days.
298 The
median time-
weighted average of hypotension was 0.10 mm
299 Median times were 5 minutes before and 20 minutes after
300 Median time with glucose levels less than 70 mg/dL was 5